Urologic oncology · 2026
Etiology of testosterone deficiency after radical prostatectomy.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hammad Muhammed A M, Bandaru Dhiresh, Furlan Vada, Hwang Yeagyeong, Yafi Faysal A, Daneshvar Michael, Lee David, Ahlering Thomas, Shahait Mohammed
Аннотация
INTRODUCTION: Testosterone deficiency (TD) may occur after radical prostatectomy (RP). Guidance on prevalence, mechanisms, and testosterone-replacement therapy (TRT) safety remains limited.
OBJECTIVE: To summarize contemporary evidence on the etiology of post-RP TD.
METHODS: A PRISMA-ScR scoping review identified English-language human studies reporting the etiology of post-RP TD. Fourteen of 186 screened articles met the inclusion criteria.
RESULTS: TD develops in 20% to 30% of men within 4 weeks and persists in 37.5% by day 90. Proposed mechanisms described in the literature include perioperative venous, ischemic, and neuroendocrine perturbations, though supporting evidence remains limited and largely indirect.
CONCLUSIONS: One-third of men experience transient or persistent TD post-RP owing to venous, ischemic, and endocrine factors; most normalize within a year. Routine androgen surveillance and prospective trials are warranted to refine the timing and long-term outcomes of administering exogenous testosterone post-RP.
OBJECTIVE: To summarize contemporary evidence on the etiology of post-RP TD.
METHODS: A PRISMA-ScR scoping review identified English-language human studies reporting the etiology of post-RP TD. Fourteen of 186 screened articles met the inclusion criteria.
RESULTS: TD develops in 20% to 30% of men within 4 weeks and persists in 37.5% by day 90. Proposed mechanisms described in the literature include perioperative venous, ischemic, and neuroendocrine perturbations, though supporting evidence remains limited and largely indirect.
CONCLUSIONS: One-third of men experience transient or persistent TD post-RP owing to venous, ischemic, and endocrine factors; most normalize within a year. Routine androgen surveillance and prospective trials are warranted to refine the timing and long-term outcomes of administering exogenous testosterone post-RP.